510(k) device
microINR System
Iline Microsystems, S.L. · Test, Time, Prothrombin (GJS, Class II) · First FDA decision Jan 25, 2019, newest Jul 21, 2025Anemia, clotting and blood disordersStroke prevention in atrial fibrillation
Last checked: Nov 19, 2026Source: FDA, CMS, ClinicalTrials.gov, PubMed
FDA decisions
5
510(k) pathway
Device trials
0
Naming "microINR"
MAUDE reports
0
Brand "microINR", since 2015
PubMed studies
7
Mentioning "microINR"
AI summary across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, MAUDE and PubMed data on this page, plus web searches for payment facts.
Product review deck
A slide deck reviewing microINR System
About ten slides on the technology, clinical evidence, regulatory history and commercialization, built with AI from the data on this page and web research, with sources. Download it as PowerPoint to edit or as PDF to share.
- Executive summary and key facts
- Technology
- Clinical evidence and trials
- Regulatory history and safety
- Reimbursement, market and competition
- Risks, outlook and sources
AI-written from public data and may contain mistakes. Check each fact against its source before relying on it. Not investment, legal, reimbursement or medical advice.
FDA decisions
The newest 5 of 5 decisions filed under this name.
- microINR System510(k)
K251564 · Decided Jul 21, 2025 · 60 days after receipt
Device type: Test, Time, Prothrombin (GJS) · Laboratory Medicine & Pathology
- microINR System510(k)
K243543 · Decided Feb 27, 2025 · 104 days after receipt
Device type: Test, Time, Prothrombin (GJS) · Laboratory Medicine & Pathology
- microINR System510(k)
K231711 · Decided Jul 11, 2023 · 29 days after receipt
Device type: Test, Time, Prothrombin (GJS) · Laboratory Medicine & Pathology
2 more FDA decisions with a free account
Medicare coverage
National and local coverage documents whose titles match this device or its device type. Payment add-ons (NTAP, pass-through, TCET) and likely codes are covered in the summary above.
- Home Prothrombin Time/International Normalized Ratio (PT/INR) Monitoring for Anticoagulation ManagementNational determinationOn the books190.11Updated Nov 4, 2026
- Prothrombin Time (PT)National determinationOn the books190.17Updated Oct 1, 2026
- Prothrombin Time (INR) Monitor for Home Anticoagulation ManagementNational analysisReview closedCAG-00087RUpdated Sep 21, 2026
- Prothrombin Time and Partial Thromboplastin Time (Revision of ICD-9-CM Codes for Swelling of Limb)Coding analysisReview closedCAG-00201NUpdated Sep 15, 2026
- Prothrombin Time and Partial Thromboplastin Time (Revision of ICD-9-CM Codes for Pre-operative Examinations)Coding analysisReview closedCAG-00184NUpdated Sep 15, 2026
- Prothrombin Time and Fecal Occult Blood (Revision of ICD-9-CM Codes for Injury to Gastrointestinal Tract)Coding analysisReview closedCAG-00187NUpdated Sep 15, 2026
- Prothrombin Time (PT) NCD 190.17 (Addition of ICD-9-CM diagnosis code 197.7 Secondary Malignant Neoplasm of Liver)Coding analysisReview closedCAG-00404NUpdated Sep 15, 2026
- Prothrombin Time (PT) and Partial Thromboplastin Time (PTT) tests (Removal of Unspecified Joint Replacements)Coding analysisReview closedCAG-00246NUpdated Sep 15, 2026
Clinical trials
Device studies on ClinicalTrials.gov that name "microINR", any status and sponsor, newest update first.
No registered device study names "microINR".
Adverse event reports (MAUDE)
Reports received since 2015 naming the brand "microINR", and for the whole product code for context.
This brand
0 reports: 0 malfunction, 0 injury, 0 death
Whole product code GJS
12,207 reports: 11,507 malfunction, 644 injury, 34 death
Newest reports for this brand
No MAUDE reports name this brand.
Recalls
From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.
No recall in FDA's data is linked to these FDA numbers.
Published research
The most relevant PubMed records for "microINR"[tiab]. The summary above synthesizes these.
- [Comparison of point of care capillary international normalized ratio (INR) with INR measured in venous samples].
Roco Á, Nieto E, Quintana M, et al. · Rev Med Chil · 2019Comparative Study
- Performance of the microINR Point-of-Care System: A Multicenter Clinical Trial.
Refaai MA, Shah V, Fernando R · Thromb Haemost · 2020Clinical Trial, Comparative Study
- Performance evaluation of the microINR® point-of-care INR-testing system.
Joubert J, van Zyl MC, Raubenheimer J · Int J Lab Hematol · 2018Evaluation Study
- Analytical accuracy and precision of two novel Point-of-Care systems for INR determination.
van den Besselaar AM, van der Meer FJ, Abdoel CF, et al. · Thromb Res · 2015Comparative Study, Research Support, Non-U.S. Gov't
- Analytical performance and user-friendliness of four point-of-care measuring systems for monitoring prothrombin time international normalized ratio in the hands of the intended users.
Kur DK, Eriksson Boija E, Morken C, et al. · Diagnosis (Berl) · 2025
- The microINR portable coagulometer: analytical quality and user-friendliness of a PT (INR) point-of-care instrument.
Larsen PB, Storjord E, Bakke Å, et al. · Scand J Clin Lab Invest · 2017
- Performance of the microINR Point-of-Care System Used by Self-Testing Patients: A Multicenter Clinical Trial.
Refaai MA, Jacobson AK, Rosenfeld JC, et al. · TH Open · 2021
Other devices of this type
Also filed under product code GJS.
- CoaguChek XS Plus SystemRoche Diagnostics · 510(k) 2025
- Coag-Sense Prothrombin (PT) / INR Monitoring System for Patient Self-TestingCoagusense, Inc. · 510(k) 2022
- CoaguChek XS Pro SystemRoche Diagnostics · 510(k) 2018
- Hemosil Recombiplastin 2G (8 Ml Vial)Instrumentation Laboratory CO · 510(k) 2014
- Coaguchek Xs SystemRoche Diagnostics Corp. · 510(k) 2007
- Xprecia Prime Coagulation SystemUniversal Biosensors Pty, Ltd. · 510(k) 2024
- i-STAT PTplus Cartridge with the i-STAT 1 SystemAbbott Laboratories · 510(k) 2023
- STA- NeoPTimalDiagnostica Stago S.A.S · 510(k) 2022
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.